Impact of Age and Geriatric Co-morbidities on Lymphocyte Phenotype in Patients 70 Years of Age and Older

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04772092

Acronym

PHENOGERIA

Enrollment

Registered

2021-02-26

Start date

2021-11-30

Completion date

2021-11-30

Last updated

2022-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatrics Immunosenescence

Brief summary

An individual's immune profile changes with age, and can sometimes be involved in the development of certain diseases such as infections or cancers, in a process called immunosenescence. Some data tend to show that there is a link between this immune profile and geriatric fragility (autonomy, difficulties with walking, memory, undernutrition, co-morbidities, depression). The aim of this study is to describe this profile, or immune phenotype, and to see if there is a link with the different aspects of geriatric assessment in patients without cancer or infection. In addition, these data will serve as a basis for comparison with the same analyses performed on breast cancer patients at the Centre Georges François Leclerc.

Interventions

BIOLOGICALBlood samples

during the routine blood test, collection of additional blood samples: * 1 x 5 mL heparinized tube for plasma collection and storage * 1 heparinized 5 mL tube for immunophenotyping * 4 x 10 mL EDTA tubes for white blood cell (WBC) collection and cryopreservation

OTHERData collection

* clinical examination data * test results to measure the degree of geriatric fatigability * Frailty screening questionnaire for neoplasia patients (G8 score)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

70 Years to No maximum

Inclusion criteria

* Person who has not opposed to inclusion in the study * Male or female aged 70 and over admitted to the Champmaillot Geriatric Center on an inpatient or outpatient basis.

Exclusion criteria

* Person not affiliated to national health insurance system * Person subject to a measure of legal safeguard (curatorship, etc) * Person with an acute infection * Person with suspected cancer or active cancer * Long-term immunosuppressive or corticosteroid therapy * HIV and/or HBV and/or HCV positive serology

Design outcomes

Primary

Measure	Time frame	Description
percentage of immune cells in peripheral blood	At inclusion	technique used: flow cytometry

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026